Akero Therapeutics, Inc. (AKRO)

Over the past six months, Akero Therapeutics' stock has experienced significant events and performance. The stock price increased by 32.67% over the last six months and 12.84% in the past month. Positive clinical trial results from the SYMMETRY and HARMONY trials have contributed to positive market sentiment. Novo Nordisk announced its intent to acquire Akero Therapeutics for up to $5.2 billion, causing Akero's shares to rise. Analyst coverage has been mixed, with some firms initiating or maintaining positive ratings, while others have cut their ratings or price objectives. Akero Therapeutics reported ($0.86) earnings per share for a recent quarter, beating the consensus estimate of ($0.97).

As a clinical-stage biotechnology company, Akero Therapeutics does not currently have commercialized products or services that would exhibit demand seasonality. Its primary activities involve research and development and advancing its drug candidates through clinical trials.

Akero Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for metabolic diseases, particularly MASH. Their lead product candidate, efruxifermin (EFX), is being evaluated in Phase 3 studies. Akero has a license agreement with Amgen Inc. As a clinical-stage company, Akero Therapeutics does not currently generate revenue from product sales, with its operations primarily funded through equity financing.

Akero Therapeutics is headquartered in South San Francisco, California. Its stock is traded on the NASDAQ Global Select Market and is also listed on several European exchanges, including the Berlin Stock Exchange, Frankfurt Stock Exchange, Stuttgart Stock Exchange, Dusseldorf Stock Exchange, and Milan Stock Exchange.

Akero Therapeutics' brand reputation has been shaped by its clinical progress and the acquisition announcement. Positive results from trials have bolstered its scientific credibility. The acquisition by Novo Nordisk enhances Akero's reputation, validating its scientific approach. However, some negative ratings and insider selling events could be perceived as less positive, but the overall sentiment is positive.

Akero Therapeutics is primarily owned by institutional shareholders, who hold approximately 115.32% of the total shares outstanding, while insiders own about 25.15% of the company. Major institutional owners include Janus Henderson Group Plc, BlackRock, Inc., and General Atlantic Llc. Versant Venture Capital VI LP is the largest individual shareholder. Key figures associated with the company include Andrew Cheng (President and CEO) and Timothy Rolph (Chief Scientific Officer).